Adjuvant Development within the context of a vaccine to protect against B. pertussis for use in newborns.

在疫苗背景下开发佐剂，以预防新生儿感染百日咳博德特氏菌。

• 批准号: 10223090
• 负责人: OFER LEVY
• 金额: $ 372.16万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2022-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10223090
• 关键词: Adjuvant; Agonist; Bordetella pertussis; Development; Disease; Human; Immunologics; Investigation; Licensure; Newborn Infant; Support Contracts; TLR7 gene; Testing; Vaccines; human disease; pathogen; small molecule

This contract supports the development of an adjuvant through immunological characterization studies and compound optimization, up to and including IND-enabling studies. The main emphasis will be on testing and further development of the adjuvant for human licensure as a component of a licensed or investigational vaccine to protect against one or more non-HIV disease pathogens relevant to human disease.

该合同支持通过免疫学表征研究和化合物优化开发佐剂，包括IND使能研究。主要重点将是测试和进一步开发用于人类许可的佐剂，作为许可或研究疫苗的组成部分，以防止一种或多种与人类疾病相关的非HIV疾病病原体。